We scan new podcasts and send you the top 5 insights daily.
Dr. Bazanova says she orders both in practice because IHC measures surface protein while NGS reads gene-level changes, and each can trigger different therapy. A high IHC result without a MET mutation or amplification is not discordant; it tells a separate part of the tumor's biology.
Relying solely on Next-Generation Sequencing (NGS) is insufficient for HER2 testing in biliary tract cancers. Data shows NGS misses up to 15% of patients with HER2 overexpression detected by immunohistochemistry (IHC). Performing both tests is essential to avoid denying patients effective targeted therapies.
The SAVANNAH study showed that targeting MET amplification after TKI failure is only effective with stringent diagnostic criteria (e.g., IHC 3+ in >90% of cells). Lower cutoffs lead to poor outcomes, highlighting the need for precise biomarker testing to select patients for this therapy.
When a colorectal tumor loses HER2 protein expression (IHC 0) but retains HER2 gene amplification via NGS, the decision to continue HER2-targeted therapy is guided by the amplification copy number. A low copy number argues against continuing the targeted regimen.
While PD-L1 testing by IHC is standard, the diagnostic workup for metastatic NSCLC must now also include IHC for HER2 and CMET. This is because specific antibody-drug conjugates and other agents are now approved and tied directly to the protein expression levels identified by these tests.
Dr. Bazanova says acquired MET overexpression can appear after EGFR-targeted therapy, so her standard practice is to repeat biopsy and order both NGS and IHC at progression. That acquired finding can open use of a MET-directed therapy in patients whose earlier biopsy lacked the target.
Standard Next-Generation Sequencing (NGS) reports often just state "MET amplification" without a specific copy number. To make informed treatment decisions with MET inhibitors, clinicians must proactively contact the testing company's molecular pathology department to obtain this crucial, unlisted data point.
For certain therapies like Enhertu, eligibility is based on immunohistochemistry (IHC), not NGS. Labs must run HER2 IHC in parallel because NGS, as a population-based test, can miss intratumoral heterogeneity (small clusters of positive cells) that IHC can detect, thus identifying more eligible patients for targeted therapy.
While both are used, some oncologists consider Next-Generation Sequencing (NGS) the gold standard over Immunohistochemistry (IHC) for MSI testing. NGS provides tumor mutation burden (TMB) data, which can identify rare, ultra-hypermutated but technically microsatellite-stable (MSS) tumors that are likely to respond to immunotherapy but would be missed by IHC alone.
While Next-Gen Sequencing (NGS) provides genetic data, IHC directly measures the protein, is faster, cheaper, and requires less tissue. This makes it more scalable for routine clinical use, especially with small biopsy samples. High-level IHC loss correlates well with genetic loss seen on NGS.
Despite next-generation sequencing (NGS) identifying ERBB2 amplification, clinicians still order immunohistochemistry (IHC) tests. The IHC score (e.g., 3+) provides a quantitative measure of protein expression, which can offer greater confidence in the efficacy of HER2-targeted therapies and help decide between treatment options.